Product Number |
ARP48103_P050 |
Product Page |
www.avivasysbio.com/mapt-antibody-middle-region-arp48103-p050.html |
Name |
MAPT Antibody - middle region (ARP48103_P050) |
Protein Size (# AA) |
758 amino acids |
Molecular Weight |
79 kDa |
NCBI Gene Id |
4137 |
Host |
Rabbit |
Clonality |
Polyclonal |
Concentration |
0.5 mg/ml |
Gene Full Name |
Microtubule-associated protein tau |
Alias Symbols |
TAU, MSTD, PPND, DDPAC, MAPTL, MTBT1, MTBT2, tau-40, FTDP-17, PPP1R103 |
Peptide Sequence |
Synthetic peptide located within the following region: RGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPG |
Product Format |
Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reference |
Reynolds,M.R., (2006) Biochemistry 45 (13), 4314-4326 |
Description of Target |
MAPT is differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. The mutations in the gene have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. |
Protein Interactions |
Ywhaz; Prkaca; STUB1; PHGK; SRC; PRKAR1A; GSK3B; FYN; DCTN1; CSNK1A1; CDK2; AKT1; ABL1; YWHAQ; SGK1; MARK2; MARCH7; TUBB3; TUBA1B; UBC; TUBA4A; MARK4; PEG10; MARK3; MARK1; MAPK13; MAPK11; MAPK8; mapk14; Mapk12; LIMS1; HSPA1A; PPP5C; PPP2R4; CAPN2; PKN1; H |
Reconstitution and Storage |
For short term use, store at 2-8C up to 1 week. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles. |
Datasheets/Manuals |
Printable datasheet for anti-MAPT (ARP48103_P050) antibody |
Blocking Peptide |
For anti-MAPT (ARP48103_P050) antibody is Catalog # AAP48103 (Previous Catalog # AAPS21802) |
Immunogen |
The immunogen is a synthetic peptide directed towards the middle region of human MAPT |
Uniprot ID |
P10636-8 |
Protein Name |
Microtubule-associated protein tau |
Protein Accession # |
NP_005901 |
Purification |
Affinity Purified |
Nucleotide Accession # |
NM_005910 |
Tested Species Reactivity |
Human, Mouse |
Gene Symbol |
MAPT |
Predicted Species Reactivity |
Human, Mouse, Rat, Pig |
Application |
IHC, WB |
Predicted Homology Based on Immunogen Sequence |
Human: 100%; Mouse: 86%; Pig: 79%; Rat: 86% |
Image 1 | E.Coli: expressed human Tau-C, E.Coli: expressed human Tau-E, E.Coli: expressed human Tau-F, E.Coli: expressed human Tau-B, E.Coli: expressed human Fetal-Tau, E.Coli: expressed human Tau-D
| Researcher: Max Holzer, Paul Flechsig Institut of Brain Research, University of Leipzig
Application: Western blotting
Species + Tissue/Cell type:
Lane 1: 10ug E.Coli: expressed human Tau-C
Lane 2: 10ug E.Coli: expressed human Tau-E
Lane 3: 10ug E.Coli: expressed human Tau-F
Lane 4: 10ug E.Coli: expressed human Tau-B
Lane 5: 10ug E.Coli: expressed human Fetal-Tau
Lane 6: 10ug E.Coli: expressed human Tau-D
Primary antibody dilution: 1:1000
Secondary antibody: Donkey anti-rabbit-HRP
Secondary antibody dilution: 1:10,000 |
|
Image 2 | mouse cortex
| Sample Type: A: Transgenic hTau P301L mouse cortex
B: Tau-Ko mouse cortex
C: WT mouse cortex Primary Antibody Dilution: 1:1000Secondary Antibody: Anti-rabbit-biotin / Avidin-HRP Secondary Antibody Dilution: 1:1000 /1:2000 Color/Signal Descriptions: Dark grey: MAPT Gene Name: MAPTSubmitted by: Max Holzer,
Paul Flechsig Institut of Brain Research,
University of Leipzig |
|
Image 3 |
| 25 ug of the indicated Human whole cell extracts was loaded onto a 12% SDS-PAGE gel. 3 ug/mL of the antibody was used in this experiment. The peptide sequence is present in a 45 kDa isoform. The protein may be modified by acetylation, glycosylation, and phosphorylation.
|
|